Paxlovid and Lagevrio cut deaths and hospitalization in Omicron patients

9 October 2023

New Cleveland Clinic-led research shows that the COVID-19 antivirals Paxlovid (nirmatrelvir) and Lagevrio (molnupiravir)—from Pfizer (NYSE: PFE) and Merck & Co (NYSE: MRK), respectively - reduce risk of hospitalization and death in high-risk patients with mild disease, even with Omicron subvariants.

The observational study, published in JAMA Network Open, analyzed nearly 70,000 patients diagnosed with COVID-19 at Cleveland Clinic between April 2022 to February 2023, finding that nirmatrelvir lowered risk of death by 84% and molnupiravir by 77% compared to no treatment.

"The findings regarding the effectiveness of Lagevrio are especially crucial due to notable Paxlovid drug-drug interactions"Both drugs also reduced combined risk of hospitalization and death by more than 40%. Importantly, the treatments were effective across all patient subgroups and against newer strains like BQ.1.1 and XBB.1.5.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK